In our analysis, patients with EGFR ex20ins mutant NSCLC appear to benefit from the use of anti-angiogenesis agents on median OS, especially in the patients bearing EGFR ex20ins near-loop variants. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.